Biopharmaceuticals
Oncology
FDA
News Release - January 7, 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Source: Sopherion Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.